Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) saw an uptick in trading volume on Wednesday . 539,897 shares changed hands during trading, an increase of 130% from the previous session’s volume of 234,870 shares.The stock last traded at $7.14 and had previously closed at $7.65.

Several research firms have recently commented on VTAE. Zacks Investment Research cut Vitae Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. JMP Securities cut Vitae Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 4th. Wedbush reiterated an “outperform” rating and set a $23.00 target price on shares of Vitae Pharmaceuticals in a research note on Wednesday, May 25th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Vitae Pharmaceuticals in a research note on Friday, June 10th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $16.65.

The stock has a 50-day moving average of $9.64 and a 200 day moving average of $8.51. The stock’s market cap is $205.92 million.

Vitae Pharmaceuticals (NASDAQ:VTAE) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.36) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.05. During the same period in the prior year, the company earned ($0.45) earnings per share. The business’s revenue was down 98.0% compared to the same quarter last year. On average, equities analysts predict that Vitae Pharmaceuticals Inc. will post ($1.64) EPS for the current fiscal year.

A hedge fund recently bought a new stake in Vitae Pharmaceuticals stock. Dimensional Fund Advisors LP acquired a new stake in Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 73,607 shares of the company’s stock, valued at approximately $1,332,000. Dimensional Fund Advisors LP owned about 0.34% of Vitae Pharmaceuticals at the end of the most recent reporting period.

Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.